Results 101 to 110 of about 54,096 (328)

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Blood Advances, 2021
Key Points Peritransplantation ruxolitinib was safe and well tolerated in patients with myelofibrosis, with MTD determined as 10 mg twice daily.
H. Ali, N. Tsai, T. Synold, S. Mokhtari, Weimin Tsai, J. Palmer, T. Stiller, A. Salhotra, S. Rahmanuddin, V. Pullarkat, J. Cai, A. Stein, S. Forman, G. Marcucci, M. Mei, D. Snyder, R. Nakamura   +16 more
semanticscholar   +1 more source

Familial myelofibrosis. [PDF]

Archives of Disease in Childhood, 1980
Two siblings developed a fulminant fatal myeloproliferative disease at 7 and 8 weeks of age. The illness presented with pallor, haemorrhagic symptoms, and hepatosplenomegaly, and the blood picture was that of pancytopenia and leucoerythroblastosis. Bone marrow histology showed reduced haemopoiesis with generalised fibrosis.
C A, Sieff, P, Malleson
openaire   +2 more sources

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis

Haematologica, 2012
Background The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis.
Thomas Buhr, Konnie Hebeda, Vassiliki Kaloutsi, Anna Porwit, Jon Van der Walt, Hans Kreipe   +5 more
doaj   +1 more source

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis

Blood Cancer Journal, 2021
Myelofibrosis is a myeloproliferative neoplasm associated with constitutional symptoms, increasing splenomegaly, and worsening cytopenias. Janus kinase (JAK) inhibitors have been used for the treatment of myelofibrosis for several years, but there is a ...
Léa Sureau, C. Orvain, J. Ianotto, V. Ugo, J. Kiladjian, D. Luque Paz, J. Riou   +6 more
semanticscholar   +1 more source

Primary myelofibrosis L.

Онкогематология, 2014
Literature data of idiopathic myelofibrosis are presented: classification, diagnostic criteria, morphological and molecular features. Particular attention is given to therapy of various clinical forms of primary myelofibrosis.
L. M. Meshcheryakova, O. V. Porotkova, L. G. Kovaleva, L. Yu. Kolosova, S. N. Bychkova   +4 more
doaj   +3 more sources

Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. [PDF]

, 2013
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.Reported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation.
Andersson, Therese M-L, Björkholm, Magnus, Derolf, Asa Rangert, Dickman, Paul W, Eloranta, Sandra, Hultcrantz, Malin, Kristinsson, Sigurdur Yngvi, Landgren, Ola   +7 more
core   +1 more source

Hetrombopag: A promising thrombopoietin receptor agonist for the treatment of primary and secondary immune thrombocytopenia

Rheumatology &Autoimmunity, EarlyView.
This review seeks to provide a thorough synthesis of the existing literature on the role of thrombopoietin receptor agonists in the treatment of primary and secondary immune thrombocytopenia, with particular emphasis on the compound Hetrombopag. Abstract Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by a platelet count below
Jiaqi Hu, Zhida Fu, Xia Xu, Zhengyi Jin, Xinyu Qian, Weiyu Tao, Taiyan Ma, Dongbao Zhao, Jie Gao   +8 more
wiley   +1 more source

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Journal of Clinical Oncology, 2017
Purpose To develop a prognostic system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and Methods The study included 805 patients with PMF age ≤ 70 years recruited from
P. Guglielmelli, T. Lasho, G. Rotunno, M. Mudireddy, C. Mannarelli, M. Nicolosi, Annalisa Pacilli, A. Pardanani, E. Rumi, V. Rosti, C. Hanson, F. Mannelli, R. Ketterling, N. Gangat, A. Rambaldi, F. Passamonti, G. Barosi, T. Barbui, M. Cazzola, A. Vannucchi, A. Tefferi   +20 more
semanticscholar   +1 more source

IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis

Aging, 2021
Primary myelofibrosis is a Ph-negative chronic myeloproliferative neoplasm characterized by bone marrow fibrosis and associated with the involvement of several pathways, in addition to bone marrow microenvironment alterations, mostly driven by the ...
L. Longhitano, D. Tibullo, N. Vicario, C. Giallongo, E. La Spina, A. Romano, S. Lombardo, M. Moretti, Francesco Masia, A. R. Coda, S. Venuto, Paolo Fontana, R. Parenti, G. Li Volti, M. Di Rosa, G. Palumbo, A. Liso   +16 more
semanticscholar   +1 more source

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report [PDF]

, 2012
Background Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia.
COLOMBA, Claudia, LALICATA, Francesco, Rubino, R, Siracusa, L, TITONE LANZA DI SCALEA, Lucina, Tolomeo, M., Trizzino, M   +6 more
core   +2 more sources